Company Overview and News
Brave Warrior Advisors, LLC Buys Nielsen Holdings PLC, Sells Brookfield Asset Management Inc, IQVIA Holdings Inc, Express Scripts Holding Co
Good day and welcome to the Veeco Instruments First Quarter 2018 Earnings Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Anthony Bencivenga, Investor Relations. Please go ahead.
The following slide deck was published by Veeco Instruments Inc. in conjunction with their 2018 Q1 earnings call.
Table of Contents
PLAINVIEW, N.Y., May 07, 2018 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (Nasdaq:VECO) today announced financial results for its first quarter ended March 31, 2018. Results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”) and are also reported adjusting for certain items (“Non-GAAP”). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release.
Amazon.com, Alibaba Group Holdings, Visa Inc., Apple Inc., and Taiwan Semiconductor Manufacturing are the largest five individual stock positions.
PLAINVIEW, N.Y., April 11, 2018 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ:VECO) plans to release its first quarter 2018 financial results after the market close on Monday, May 7, 2018. The company will host a conference call to review these results starting at 5:00pm ET that day.
PLAINVIEW, N.Y., April 10, 2018 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (Nasdaq:VECO) today announced that ON Semiconductor (Nasdaq:ON) has ordered its Propel® High-volume Manufacturing (HVM) Gallium Nitride (GaN) Metal Organic Chemical Vapor Deposition (MOCVD) system. Based on its successful beta evaluation of the Propel HVM tool, ON Semiconductor ordered the production-level Propel system for GaN power electronics manufacturing.
PLAINVIEW, N.Y., March 27, 2018 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ:VECO) today announced it has completed installation of its 100th automated Molecular Beam Epitaxy (MBE) system. The installation of Veeco’s GEN10™ MBE System last month at Silanna Semiconductor PTY Ltd. in Australia marks this significant company milestone. The company also operates a Veeco Dual GEN200® MBE System for production of advanced nitride compound semiconductor devices including ultraviolet light emitting diodes (UV-LEDs).
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
In December of last year, Micron Technology sued United Microelectronics Corp. and Jinhua Integrated Circuit for DRAM trade secret infringement.
WATERLOO, ON / ACCESSWIRE / March 6, 2018 / VueReal Inc., a developer of key technologies for micro-LED displays, announced today the initial closing of its $10.5 million (USD) Series A funding led by the venture arm of a large Asian company and a leading North American vendor focused on startups with emerging technology. VueReal will use the funding to accelerate the development of micro-LED technologies by expanding its team and launching its advanced micro-device development and characterization center.
12h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
12h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
22h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET